266 related articles for article (PubMed ID: 27855197)
1. Efficacy of Anti-VEGF/VEGFR Agents on Animal Models of Endometriosis: A Systematic Review and Meta-Analysis.
Liu S; Xin X; Hua T; Shi R; Chi S; Jin Z; Wang H
PLoS One; 2016; 11(11):e0166658. PubMed ID: 27855197
[TBL] [Abstract][Full Text] [Related]
2. Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials.
Li Y; Liang XY; Yue YQ; Sheng L; Liu JK; Wang ZY; Chen G
Tumour Biol; 2016 May; 37(5):6297-306. PubMed ID: 26619847
[TBL] [Abstract][Full Text] [Related]
3. Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats.
Yildiz C; Kacan T; Akkar OB; Karakus S; Kacan SB; Ozer H; Cetin A
Reprod Sci; 2015 Nov; 22(11):1445-51. PubMed ID: 25963915
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
Tandle A; Libutti SK
Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis.
Iacovelli R; Sternberg CN; Porta C; Verzoni E; de Braud F; Escudier B; Procopio G
Curr Drug Targets; 2015; 16(2):164-70. PubMed ID: 25410406
[TBL] [Abstract][Full Text] [Related]
6. The relationship between microvessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions.
Bourlev V; Volkov N; Pavlovitch S; Lets N; Larsson A; Olovsson M
Reproduction; 2006 Sep; 132(3):501-9. PubMed ID: 16940291
[TBL] [Abstract][Full Text] [Related]
7. Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis.
Novella-Maestre E; Carda C; Noguera I; Ruiz-Saurí A; García-Velasco JA; Simón C; Pellicer A
Hum Reprod; 2009 May; 24(5):1025-35. PubMed ID: 19189995
[TBL] [Abstract][Full Text] [Related]
8. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.
Roodhart JM; Langenberg MH; Witteveen E; Voest EE
Curr Clin Pharmacol; 2008 May; 3(2):132-43. PubMed ID: 18690886
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic Effect of Dopamine and Dopaminergic Agonists as an Adjuvant Therapeutic Option in the Treatment of Cancer, Endometriosis, and Osteoarthritis.
Mendoza-Torreblanca JG; Cárdenas-Rodríguez N; Carro-Rodríguez J; Contreras-García IJ; Garciadiego-Cázares D; Ortega-Cuellar D; Martínez-López V; Alfaro-Rodríguez A; Evia-Ramírez AN; Ignacio-Mejía I; Vargas-Hernández MA; Bandala C
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373348
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic treatment strategies for the therapy of endometriosis.
Laschke MW; Menger MD
Hum Reprod Update; 2012; 18(6):682-702. PubMed ID: 22718320
[TBL] [Abstract][Full Text] [Related]
11. Ginsenoside Rg3 inhibits angiogenesis in a rat model of endometriosis through the VEGFR-2-mediated PI3K/Akt/mTOR signaling pathway.
Cao Y; Ye Q; Zhuang M; Xie S; Zhong R; Cui J; Zhou J; Zhu Y; Zhang T; Cao L
PLoS One; 2017; 12(11):e0186520. PubMed ID: 29140979
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
Artini PG; Ruggiero M; Monteleone P; Carpi A; Cristello F; Cela V; Genazzani AR
Biomed Pharmacother; 2008; 62(6):373-7. PubMed ID: 18037256
[TBL] [Abstract][Full Text] [Related]
13. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.
Qi WX; Sun YJ; Tang LN; Shen Z; Yao Y
Crit Rev Oncol Hematol; 2014 Mar; 89(3):394-403. PubMed ID: 24182420
[TBL] [Abstract][Full Text] [Related]
14. Amount of mRNA and localization of vascular endothelial growth factor and its receptors in the ovarian follicle during estrous cycle of water buffalo (Bubalus bubalis).
Babitha V; Panda RP; Yadav VP; Chouhan VS; Dangi SS; Khan FA; Singh G; Bag S; Taru Sharma G; Silvia WJ; Sarkar M
Anim Reprod Sci; 2013 Mar; 137(3-4):163-76. PubMed ID: 23375984
[TBL] [Abstract][Full Text] [Related]
15. Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review).
Song G; Li Y; Jiang G
Oncol Rep; 2012 Dec; 28(6):1935-44. PubMed ID: 22993103
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
17. [Anti-angiogenesis targeting drugs: a review].
Jia K; Li J
Ai Zheng; 2008 Apr; 27(4):442-6. PubMed ID: 18423135
[TBL] [Abstract][Full Text] [Related]
18. TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.
Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong D; Kurzrock R
Mol Cancer Ther; 2016 Oct; 15(10):2475-2485. PubMed ID: 27466356
[TBL] [Abstract][Full Text] [Related]
19. Targeting VEGF/VEGFR in the treatment of psoriasis.
Li W; Man XY; Chen JQ; Zhou J; Cai SQ; Zheng M
Discov Med; 2014 Sep; 18(98):97-104. PubMed ID: 25227750
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer?
Raben D; Helfrich B
Clin Lung Cancer; 2004 Jul; 6(1):48-57. PubMed ID: 15310417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
